Rimantadine-STI 50 mg (20 tablets)

The instruction for medical use of Rimantadin-STI Torgovoye medicine a name of Rimantadin-STI the International unlicensed name Rimantadinum Dosage Form of the Tablet, 50 mg Structure One tablet contains active agent - Rimantadinum a hydrochloride – 50 mg excipients: lactoses monohydrate, potato starch, calcium stearate, talc. Description of the Tablet of white color, ploskotsilindrichesky form. Pharmacotherapeutic group Anti-infectious drugs for system use. Antiviral drugs for system use. Cyclic amines. Rimantadinum. The ATX J05AC02 code the Pharmacological Pharmacokinetics Later properties of intake Rimantadinum is well soaked up in digestive tract, has high bioavailability, well gets into all fabrics and liquids of an organism, into liquor. Communication with proteins of blood plasma - about 40%. The maximum concentration (Cmax) in blood plasma is reached in 5-7 hours. Rimantadinum is intensively metabolized in a liver, is exposed to hydroxylation, conjugation and a glyukuronization. Elimination half-life (T1/2) averages 25 hours, at elderly – 32 h, children have 13-38 h. 15% are removed mainly with urine in the form of metabolites, – in not changed look through kidneys. In chronic kidney disease the elimination half-life increases twice. At persons with a renal failure and at elderly people Rimantadinum can collect in toxic concentration if the dose is not adjusted in proportion to reduction of the clearance of creatinine (CC). The pharmacodynamics Rimantadinum – derivative an adamantana, has the significant antiviral activity. Drug is effective against an influenza virus of type A, does not possess or possesses small action against influenza viruses V. Rimantadin inhibits replication of a virus at early stages of a cycle, perhaps, breaking forming of a viral envelope. In antiviral effect of Rimantadinum concerning an influenza virus And specific protein of a gene of M2 of virion is important. In vitro Rimantadinum inhibits replication of three antigenic subtypes of an influenza virus allocated at the person And – H1N1, H2N2 and H3N2. Rimantadinum does not affect immunogenetic properties of the inactivated flu A vaccine. Indications - prevention and early treatment of flu A at adults and children are more senior than 7 years the Route of administration and doses Inside after a meal, washing down with water. Treatment of flu should be begun during 24-48 h after emergence of symptoms of a disease. The adult in the first day appoint 100 mg 3 times a day, in the second and third days on 100 mg 2 times a day, in the fourth and fifth day on 100 mg once a day. In the first day of a disease the drug use once in a dose of 300 mg is possible. To children aged from 7 up to 10 years appoint 50 mg 2 times a day, from 11 to 14 years - 50 mg 3 times a day. 14 years - doses for adults are more senior. Accept within 5 days. For prevention of flu adult appoint 50 mg during up to 30 days once a day. To children is more senior than 7 years - 50 mg during up to 15 days once a day. Side effects - dryness in a mouth, nausea, vomiting, loss of appetite, pain in epigastriums, a meteorism - a headache, dizziness, insomnia, neurologic reactions, disturbance of concentration of attention, drowsiness, uneasiness, hyperexcitability, fatigue - a hyperbilirubinemia - allergic reactions (skin rash, an itching, a small tortoiseshell) of the Contraindication - hypersensitivity to Rimantadinum and excipients of drug - acute diseases of a liver - acute and chronic diseases of kidneys - a thyrotoxicosis - pregnancy and the period of a lactation - children's age up to 7 years - hereditary intolerance of a galactose, deficiency of Lapp-lactases enzyme, glyukozo-galaktozny malabsorption (since lactose is a part of drug) With care - arterial hypertension - epilepsy (including. in the anamnesis) - atherosclerosis of vessels of a brain - chronic kidney disease Medicinal interactions Rimantadinum reduces efficiency of antiepileptic drugs. Paracetamol and ascorbic acid reduce the maximum concentration of Rimantadinum in blood plasma by 11%. Cimetidinum reduces clearance of Rimantadinum by 18%. The adsorbents knitting and enveloping means reduce Rimantadinum absorption. The means alkalinizing urine (acetazoleamide, Natrii hydrocarbonas, etc.) enhance efficiency of Rimantadinum owing to reduction of its discharge kidneys. Special instructions patients Should be careful with digestive tract diseases, abnormal liver functions and/or kidneys easy or moderate severity, a serious illness of heart and disturbances of a warm rhythm, to elderly people. In these cases it is recommended to lower a drug dose. At instructions in the anamnesis on epilepsy and the carried-out anticonvulsant therapy against the background of use of Rimantadinum the risk of developing an epileptic seizure increases. In these cases the dose of Rimantadinum is reduced to 100 mg a day. If the attack develops, intake of Rimantadinum is stopped. Rimantadinum is not applied at children up to 7 years as the content of active agent in one tablet for this age group high. The feature of influence of drug on ability to run the vehicle or potentially dangerous mechanisms during treatment needs to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions. A form of release and packing On 10 tablets in blister strip packaging from a film of the polyvinylchloride and printing aluminum foil varnished. On the 2nd blister strip packagings together with the instruction for medical use in the state and Russian languages place in a pack from cardboard. To Store storage conditions in the dry, protected from light place, at a temperature not above 25 ºC. To store out of children's reach! Period of storage of 5 years. Not to apply after an expiration date. Prescription status Without prescription. Producer/packer of JSC Irbit Chemical Pharmaceutical Plant, Russia 623856, Sverdlovsk Region, Irbit, Kirov St., 172 Ph./fax: (34355) 3-60-90 The owner of the registration certificate of JSC Irbit Chemical Pharmaceutical Plant, Russia the Name, the address and a contact information (phone, the fax, e-mail) of the organization in the territory of the Republic of Kazakhstan, the accepting claim (offer) on quality of medicines from consumers and responsible for post-registration observation of safety of medicine: SP Utegenova B. A. 050022, Kazakhstan, Almaty, Maulenov St., 123 and, quarter 7 Ph. / fax 8 (7172) 43-95-34, ph. +77017076181 E-mail address b.utegenova_ip@mail.ru